Earlier this year, @UCL spinout company Autolus Therapeutics announced that the U.S. Food and Drug Administration (FDA) had granted marketing approval for AUCATZYL® (obecabtagene autoleucel, obe-cel), for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). UCLB has supported Autolus in protecting and licensing the obe-cel technology, enabling it to attract further capital to fund its development. More here: https://t.co/ZXqNNcT9e4 #BioPharm# #TechTransfer# #Spinouts#

In 2024 the Spinout Review anniversary has shown further commitment to nurturing university research and innovation. Spinouts represent the bridge between groundbreaking research and real-world impact, generating jobs, driving economic growth, and transforming lives. The Spinout Review has been a landmark moment for the entire tech transfer industry, kicking off a step-change in better deal-making, proliferation of tech transfer clusters and the hardwiring of spinout growth into the UK's industrial strategy. Find out more about the spinout review here: https://t.co/ZO0QIJi9pu